• 出版社/出版日：Mordor Intelligence / 2021年2月25日
|Single User||￥454,750 (USD4,250)||▷ お問い合わせ|
|Team User||￥508,250 (USD4,750)||▷ お問い合わせ|
|Corporate License||￥802,500 (USD7,500)||▷ お問い合わせ|
The Clinical Nutrition Market is estimated to be valued at USD 51,775.3 million in 2020 and USD 73610.31 million in 2026, registering a 6.04 % CAGR during the forecast period.
COVID-19 infection has become a major public health concern and clinical nutrition is playing a crucial role concerning the prevention of the infection, treatment of infection-associated malnutrition, and possibly the infection itself. For instance, the European Society for Clinical Nutrition and Metabolism has issued guidelines related to nutritional management in ICU patients infected with COVID-19. Thus, a positive impact can be expected on the market studied due to COVID-19.
Certain factors are propelling the clinical nutrition growth of the market that includes the increasing prevalence of metabolic disorders, high spending on healthcare, and the rise of the middle class in the emerging economies. Over the past decade, the prevalence of metabolic disorders has increased, in terms of raw data. According to the study of Global Coalition on Aging, November 2020, the prevalence of malnutrition in the patient hospitalized was around 31%. According to the Global Surgery Foundation, nearly 30% of worldwide diseases can be treated with surgery and require the direct care of a surgeon. Clinical nutrition plays a major part during surgeries to minimize any adverse consequences to patients and enable the surgeons to work in a controlled environment. Thus, with the rising burden of diseases and the volume of surgeries, the clinical nutrition market is expected to boost during the forecast period.
Furthermore, as per the World Ageing Population report, in 2020, about 727 million people worldwide are aged 65 years and above. This number is further expected to reach 1.5 billion by the year 2050. Elderly population is often susceptible to acquiring chronic diseases, leading to surgeries. In July 2020, Goodmills Innovation introduced ”Spermidino EVO” , wheat germ concentrate which is specifically developed for immunity boosting in ageing population. Hence, with the growing number of elderly population and development of clinical nutrition products specific to ageing population is expected to thrive the market growth.
Key Market Trends
Nutritional Support for Metabolic Disorders is Expected to have the Fastest Growth in the Route of Administration Segment
People suffering from metabolic disorders such as diabetes are at high risk of acquiring COVID-19 infection. According to a research article titled ‘Preserving Elective Surgeries in the COVID-19 Pandemic and the Future’, 2020 emergency department visits at the University of Rochester Medical Center declined by half, and patients arriving at hospitals have advanced stages major illnesses. Thus, this situation has been common among many hospitals and health systems.
And clinical nutrition is very crucial for managing diabetes to prevent infection and also among those diabetic patients infected with the virus. As a result, many of the manufacturers are introducing new products in the market. For instance, in February 2020, Galen has launched an innovative medical food PKU EASY Microtabs, for people living with the rare, inherited metabolic disorder, phenylketonuria (PKU)
Furthermore, the rising burden of metabolic disorders is also increasing the demand for clinical nutrition. According to International Diabetes Federation 2019, about over 425 million people are living with diabetes and this number is expected to reach 700 million in the year 2045. Hence, the growing burden of metabolic disorder along with the introduction of new products the market is expected to fuel in this segment.
North America holds the Majority Share in the Clinical Nutrition Market and is Expected to Follow the Same Trend over the Forecast Period
North America contributes heavily to the market growth, in comparison to the other regions, in the forecast period. The emergence of COVID-19 has led to the shortages of clinical nutritional products in this region. As per the data provided by the American Society for Parenteral and Enteral Nutrition (ASPEN) as of January 2021, certain parenteral products including Multi-Vitamin Infusion (Adult and Pediatric), Amino Acids, Potassium Acetate Injection, USP, Sodium Acetate Injection, USP, and Sodium Chloride 23.4% Injection are currently at a shortage.
In order to meet the evolving demands driven by new consumer buying behavior in the midst of the COVID-19 pandemic, manufacturers have increased production, and are working with retailers and government agencies to help ensure adequate availability of and continued access to oral clinical nutrition products.
Furthermore, some of the primary factors attributing to the growth of the clinical nutrition market include an increase in the prevalence of metabolic disorders and a rise in the geriatric population. According to the Centers for Disease Control and Prevention, the obesity rate among United States population was estimmated to be around 42.4% in 2017-2018. As per the statistics of the Center for Disease Control and Prevention, cancer and cardiovascular diseases are among the major burdens of the US healthcare sector. According to the data of the American Heart Association, in 2017, around 8,59,125 Americans died due to cardiovascular diseases. Hence, such instances indicates a rising demand for clinical nutrition products and thereby driving the market growth.
The market players are continuously engaged in growing their presence in the market through various inorganic strategies, such as acquisition, merger, strategic collaboration, and others, to gain significant market share and strengthen their product portfolios. In September 2019, Nestle SA launched an innovative drink “Boost Soothe” in the market. It is a clinical nutritional drink specially designed for cancer patients. Some of the key players in the market are Abbott Nutrition, Nestle Health Science, Baxter Healthcare, B. Braun Melsungen AG, Nutricia, BASF SE, and others.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– 3 months of analyst support
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Prevalence of Metabolic Disorders
4.2.2 High Spending on Healthcare
4.2.3 Growing Geriatric Population
4.3 Market Restraints
4.3.1 Imprecise Perception about Clinical Nutrition
4.3.2 Reduction in Birth Rates
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Route of Administration
5.1.1 Oral and Enteral
5.2 By Application
5.2.1 Nutritional Support for Malnutrition
5.2.2 Nutritional Support for Metabolic Disorders
5.2.3 Nutritional Support for Gastrointestinal Diseases
5.2.4 Nutritional Support for Cancer
5.2.5 Nutritional Support in Neurological Diseases
5.2.6 Nutritional Support in Other Diseases
5.3 By End User
5.4.1 North America
22.214.171.124 United States (By Route of Administration, By Application, and By End User)
126.96.36.199 Canada (By Route of Administration, By Application, and By End User)
188.8.131.52 Mexico (By Route of Administration, By Application, and By End User)
184.108.40.206 Germany (By Route of Administration, By Application, and By End User)
220.127.116.11 United Kingdom (By Route of Administration, By Application, and By End User)
18.104.22.168 France (By Route of Administration, By Application, and By End User)
22.214.171.124 Italy (By Route of Administration, By Application, and By End User)
126.96.36.199 Spain (By Route of Administration, By Application, and By End User)
188.8.131.52 Rest of Europe (By Route of Administration, By Application, and By End User)
184.108.40.206 China (By Route of Administration, By Application, and By End User)
220.127.116.11 Japan (By Route of Administration, By Application, and By End User)
18.104.22.168 India (By Route of Administration, By Application, and By End User)
22.214.171.124 Australia (By Route of Administration, By Application, and By End User)
126.96.36.199 South Korea (By Route of Administration, By Application, and By End User)
188.8.131.52 Rest of Asia-Pacific (By Route of Administration, By Application, and By End User)
5.4.4 Middle East and Africa
184.108.40.206 GCC (By Route of Administration, By Application, and By End User)
220.127.116.11 South Africa (By Route of Administration, By Application, and By End User)
18.104.22.168 Rest of Middle East and Africa (By Route of Administration, By Application, and By End User)
5.4.5 South America
22.214.171.124 Brazil (By Route of Administration, By Application, and By End User)
126.96.36.199 Argentina (By Route of Administration, By Application, and By End User)
188.8.131.52 Rest of South America (By Route of Administration, By Application, and By End User)
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Abbott Laboratories (Abbott Nutrition)
6.1.2 Nestle Health Science
6.1.3 Baxter Healthcare
6.1.4 B. Braun Melsungen AG
6.1.6 BASF SE
6.1.7 Perrigo Company PLC
6.1.8 Fresenius Kabi
6.1.10 AYMES International Ltd.
6.1.11 Reckitt Benckiser
6.1.12 Medifood International Ltd.
7 MARKET OPPORTUNITIES AND FUTURE TRENDS